J. Safra Sarasin Holding AG Lowers Stock Holdings in DaVita Inc. $DVA

Key Points

• J. Safra Sarasin Holding AG has significantly decreased its stake in DaVita Inc. by 89.9% during Q2, now owning only 2,221 shares, valued at $316,000.
• DaVita's stock price has been down 0.8%, with a current market cap of $9.37 billion and an average share price target from analysts at $158.00.
• Recent earnings showed DaVita reporting $2.95 earnings per share for the quarter, beating estimates and representing a 6.1% revenue increase year-over-year.

J. Safra Sarasin Holding AG reduced its stake in DaVita Inc. (NYSE:DVA - Free Report) by 89.9% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 2,221 shares of the company's stock after selling 19,741 shares during the period. J. Safra Sarasin Holding AG's holdings in DaVita were worth $316,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of DVA. Invesco Ltd. increased its holdings in shares of DaVita by 3.4% in the 1st quarter. Invesco Ltd. now owns 1,642,947 shares of the company's stock worth $251,322,000 after buying an additional 53,402 shares during the last quarter. Northern Trust Corp grew its holdings in DaVita by 20.2% during the 1st quarter. Northern Trust Corp now owns 890,632 shares of the company's stock valued at $136,240,000 after purchasing an additional 149,858 shares during the last quarter. Gates Capital Management Inc. grew its holdings in DaVita by 0.7% during the 1st quarter. Gates Capital Management Inc. now owns 722,205 shares of the company's stock valued at $110,476,000 after purchasing an additional 4,698 shares during the last quarter. Amundi boosted its position in DaVita by 16.0% in the 1st quarter. Amundi now owns 517,690 shares of the company's stock valued at $79,584,000 after buying an additional 71,304 shares during the period. Finally, Epoch Investment Partners Inc. boosted its position in DaVita by 10.7% in the 1st quarter. Epoch Investment Partners Inc. now owns 407,921 shares of the company's stock valued at $62,400,000 after buying an additional 39,485 shares during the period. 90.12% of the stock is currently owned by institutional investors.

DaVita Stock Down 0.8%

DVA opened at $131.05 on Friday. The company has a market cap of $9.37 billion, a price-to-earnings ratio of 12.89, a PEG ratio of 0.94 and a beta of 1.13. DaVita Inc. has a 52-week low of $126.07 and a 52-week high of $179.60. The firm's fifty day simple moving average is $134.81 and its two-hundred day simple moving average is $140.03.

DaVita (NYSE:DVA - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The company reported $2.95 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.70 by $0.25. The business had revenue of $3.38 billion for the quarter, compared to the consensus estimate of $3.36 billion. DaVita had a net margin of 6.35% and a return on equity of 369.39%. The company's revenue was up 6.1% compared to the same quarter last year. During the same period last year, the firm posted $2.00 earnings per share. DaVita has set its FY 2025 guidance at 10.200-11.300 EPS. On average, research analysts forecast that DaVita Inc. will post 10.76 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on DVA shares. Weiss Ratings reaffirmed a "hold (c+)" rating on shares of DaVita in a research report on Saturday, September 27th. Barclays reduced their price objective on shares of DaVita from $169.00 to $160.00 and set an "equal weight" rating for the company in a research note on Thursday, August 7th. Wall Street Zen upgraded shares of DaVita from a "hold" rating to a "buy" rating in a research note on Saturday, September 13th. Bank of America cut their price objective on shares of DaVita from $145.00 to $140.00 and set an "underperform" rating on the stock in a research note on Wednesday, September 10th. Finally, Truist Financial set a $148.00 price objective on shares of DaVita in a research note on Friday, August 8th. Four investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Reduce" and an average price target of $158.00.

Insider Buying and Selling at DaVita

In other news, insider James O. Hearty sold 2,351 shares of the firm's stock in a transaction dated Wednesday, July 23rd. The shares were sold at an average price of $150.00, for a total value of $352,650.00. Following the transaction, the insider directly owned 26,038 shares of the company's stock, valued at approximately $3,905,700. This trade represents a 8.28% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Corporate insiders own 1.50% of the company's stock.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.

Want to see what other hedge funds are holding DVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DaVita Inc. (NYSE:DVA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.